I think the potential of Agenic is to rethink how work gets done overall. It challenges all sorts of traditional orthodoxies around how organizations execute the work at hand. That's Jason Gersatus, CEO of Deloitte U.S., talking about the transformational potential of A.Gentic AI. Join him later to learn why agents are a game changer for businesses across industries.

From the opinion pages of the Wall Street Journal, this is Potomac Watch.

The Food and Drug Administration's controversial drug regulator Vinay Prad, set to exit the agency a second time,

amid more criticisms that the FDA isn't letting promising treatments through its review.

Meantime, the AI company Anthropic sues the federal government after the Trump administration

labels it a supply chain risk. Welcome, I'm Kyle Peterson with the Wall Street Journal. We're joined

today by my colleagues on the journal's opinion pages, columnist Alicia Finley, and editorial board

member Kate O'Dell. Dr. Vanai Prasad, who has had a turbulent tenure atop the FDA's Biologics

Division, is set to leave the agency a second time.

Prasad was briefly fired last year before being brought back to the FDA by Commissioner

Marty McCarrie. McCarrie is now saying that Prasad plans to leave the agency in April.

Alicia, the story is that he has a leave of absence of one year from his old job at the

University of California, San Francisco, and is now just planning to return there as scheduled.

Do you buy that argument?

No, to put it briefly.

There have been longstanding issues with his leadership at the FDA in charge of the biologics,

vaccines, and gene therapy divisions.

And he was actually pushed out last July because of some of the frustrations within the

Trump administration that he was slowing or reversing prior FDA decisions on therapies, especially gene therapies, and

kind of moving the goalposts, particularly the case in a serrepta gene therapy controversy

last summer in which he tried to pull the drug from the market, and then the FDA ended

backtracking about that. But in the intervening six or seven

...